                </a></li></ul></div><p><strong>Figure 6.  <span>Antibody responses to vaccination.</span></strong></p><a id="article1.body1.sec2.sec4.fig2.caption1.p1" name="article1.body1.sec2.sec4.fig2.caption1.p1"></a><p>A) ELISA IgG<sub>total</sub> responses in naïve uninfected mice, to peptide pools (A–N), the peptide epitope F9.1 (sequence GFAEINPIA) and recombinant vaccine antigens (AhpC, Mpa) 4 weeks after Ad5.HAV-prime/MVA.HAV-boost vaccination. C = Control (Grp3), V = Vaccine (Grp4) from Experiment 1B. B) ELISA IgG<sub>total</sub> responses to peptide pool A, the peptide epitope F9.1 (sequence GFAEINPIA) and rec.AhpC following prophylactic or therapeutic vaccination in low dose (10<sup>5</sup>) and high dose (10<sup>8</sup>) MAP K37 infection. C = Vector only control, V = Vaccine. Low dose prophylactic results correspond to Control (Grp12) and Vaccine (Grp13); Low dose therapeutic results correspond to Control (Grp17) and Vaccine (Grp18); High dose prophylactic results correspond to Control (Grp14) and Vaccine (Grp15); High dose therapeutic results correspond to Control (Grp19) and Vaccine (Grp20) as shown in <a href="#pone-0001229-g002">Fig. 2</a>.</p>
